Abeona Therapeutics (ABEO) Price & Analysis

Compare

1,430 Followers

ABEO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.93 - $7.54

Previous CloseN/A

Volume71.38K

Average Volume (3M)880.17K

Market Cap

$272.80M

Enterprise Value$176.74M

Total Cash (Recent Filing)$84.16M

Total Debt (Recent Filing)$23.98M

Price to Earnings (P/E)8.4

Beta0.96

Next Earnings

Nov 17, 2025

EPS Estimate

-0.28

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.71

Shares Outstanding51,278,538

10 Day Avg. Volume1,046,928

30 Day Avg. Volume880,166

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.65

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-176.74

Enterprise Value/Ebitda-4.79

Forecast

1Y Price Target

$20.00

Price Target Upside269.69% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Commercial LaunchThe collaboration with Stanford Medicine and activation of Lucile Packard Children's Hospital Stanford represents a key milestone in Abeona's commercial launch.

Market AccessPositive coverage for ZEVASKYN has been established with multiple large national and regional payers, including United Healthcare, the nation's largest payer.

Profitability OutlookAbeona management anticipates becoming profitable in early 2026, with expectations of reaching profitability before the end of this year depending on certain factors.

Bears Say

Market Uptake RisksRisks include slower than projected uptake for pz-cel in the United States upon market introduction and setbacks with earlier-stage pipeline programs.

Abeona Therapeutics News

Abeona Therapeutics announces employee inducement grants

Abeona Therapeutics (ABEO) has granted equity awards to new non-executive employees who joined the Company. The equity awards...

3d ago

ABEO

Abeona Therapeutics announces employee inducement grants

Abeona Therapeutics (ABEO) has granted equity awards to new non-executive employees who joined the Company. The equity awards...

1M ago

ABEO

Abeona Therapeutics’ Earnings Call Highlights ZEVASKYN Success

Abeona Therapeutics Inc (($ABEO)) has held its Q2 earnings call. Read on for the main highlights of the...

1M ago

ABEO

Abeona Therapeutics price target raised to $20 from $19 at Oppenheimer

Oppenheimer raised the firm’s price target on Abeona Therapeutics (ABEO) to $20 from $19 and keeps an Outperform...

2M ago

ABEO

Abeona Therapeutics Reports Strong Financial Turnaround

Abeona Therapeutics Inc ( ($ABEO) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ABEO

Abeona Therapeutics reports Q2 EPS ($1.71) vs (26c) last year

Reports Q2 revenue $400,000. “ZEVASKYN’s launch is demonstrating positive early momentum,” said Vish Seshadri, Chief Executive Officer of...

2M ago

ABEO

Abeona Therapeutics expects cash to fund operations for over two years

$226M in cash, cash equivalents, restricted cash and short-term investments as of June 30, 2025, expected to fund...

2M ago

ABEO

Abeona Therapeutics announces employee inducement grants

Abeona Therapeutics (ABEO) granted equity awards to new non-executive employees who joined the Company. The equity awards were...

2M ago

ABEO

AscellaHealth highlights value of HUB partnership with Abeona Therapeutics

AscellaHealth highlights the value of its HUB partnership with Abeona Therapeutics (ABEO) in the pre-and-post launch commercialization of...

2M ago

ABEO

Abeona Therapeutics Amends Loan Agreement with Avenue

An update from Abeona Therapeutics ( ($ABEO) ) is now available. On July 18, 2025, Abeona Therapeutics Inc....

3M ago

ABEO

Abeona Therapeutics’ Gene Therapy Trial for MPS IIIA: A Promising Update

Abeona Therapeutics Inc (($ABEO)) announced an update on their ongoing clinical study. Abeona Therapeutics Inc, in collaboration with...

3M ago

ABEO

Abeona announces ZEVASKYN available at new Qualified Treatment Center

Abeona Therapeutics (ABEO) announced activation of the newest Qualified Treatment Center for FDA-approved ZEVASKYN gene-modified cellular sheets. This...

3M ago

ABEO

Positive Outlook for Abeona Therapeutics Amid FDA Challenges and Promising ZEVASKYN Launch

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Abeona Therapeutics today and set a price target...

3M ago

ABEO

Fair Isaac, Aeva, Abeona, Cipher, Verisign: Insider Sales Unveiled!

Insiders have been trading these 5 stocks: (($FICO)), (($AEVA)), (($ABEO)), (($CIFR)) and (($VRSN)). Here is a breakdown of...

3M ago

ABEO

AEVA

ABEO FAQ

What was Abeona Therapeutics Inc’s price range in the past 12 months?

Abeona Therapeutics Inc lowest stock price was $3.93 and its highest was $7.54 in the past 12 months.

What is Abeona Therapeutics Inc’s market cap?

Abeona Therapeutics Inc’s market cap is $272.80M.

When is Abeona Therapeutics Inc’s upcoming earnings report date?

Abeona Therapeutics Inc’s upcoming earnings report date is Nov 17, 2025 which is in 44 days.

How were Abeona Therapeutics Inc’s earnings last quarter?

Abeona Therapeutics Inc released its earnings results on Aug 14, 2025. The company reported $1.71 earnings per share for the quarter, beating the consensus estimate of -$0.39 by $2.1.

Is Abeona Therapeutics Inc overvalued?

According to Wall Street analysts Abeona Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Abeona Therapeutics Inc pay dividends?

Abeona Therapeutics Inc does not currently pay dividends.

What is Abeona Therapeutics Inc’s EPS estimate?

Abeona Therapeutics Inc’s EPS estimate is -0.28.

How many shares outstanding does Abeona Therapeutics Inc have?

Abeona Therapeutics Inc has 51,278,538 shares outstanding.

What happened to Abeona Therapeutics Inc’s price movement after its last earnings report?

Abeona Therapeutics Inc reported an EPS of $1.71 in its last earnings report, beating expectations of -$0.39. Following the earnings report the stock price went up 10.213%.

Which hedge fund is a major shareholder of Abeona Therapeutics Inc?

Currently, no hedge funds are holding shares in ABEO

Abeona Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

48.34%

Trailing 12-Months

Asset Growth

83.75%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Abeona Therapeutics Inc

Abeona Therapeutics Inc. (ABEO) is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious genetic diseases. Based in the United States, the company's primary areas of focus include rare and life-threatening conditions such as recessive dystrophic epidermolysis bullosa (RDEB) and other genetic disorders. Abeona's core product candidates leverage advanced gene editing and cell therapy technologies aimed at providing transformative treatments for patients with unmet medical needs.

Abeona Therapeutics (ABEO) Earnings & Revenues

Historic Earnings Reports

ABEO Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call conveyed a generally positive sentiment with significant achievements like the FDA approval of ZEVASKYN and strong initial demand. Positive reimbursement trends and financial stability further support a positive outlook. However, logistical challenges in patient treatment and manufacturing scale-up present areas for improvement.View all ABEO earnings summaries

ABEO Stock 12 Month Forecast

Average Price Target

$20.00

▲(269.69% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","12":"$12","21":"$21","7.5":"$7.5","16.5":"$16.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,7.5,12,16.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.85,7.861538461538461,8.873076923076923,9.884615384615383,10.896153846153846,11.907692307692308,12.919230769230769,13.93076923076923,14.942307692307692,15.953846153846152,16.965384615384615,17.97692307692308,18.988461538461536,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.85,7.861538461538461,8.873076923076923,9.884615384615383,10.896153846153846,11.907692307692308,12.919230769230769,13.93076923076923,14.942307692307692,15.953846153846152,16.965384615384615,17.97692307692308,18.988461538461536,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.85,7.861538461538461,8.873076923076923,9.884615384615383,10.896153846153846,11.907692307692308,12.919230769230769,13.93076923076923,14.942307692307692,15.953846153846152,16.965384615384615,17.97692307692308,18.988461538461536,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.81,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.46,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.34,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.45,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >